Alzheimer’s disease doesn’t arrive suddenly. Instead, it emerges slowly, beginning with subtle changes that might be dismissed as normal aging before progressing through increasingly serious stages of ...

A team of researchers at the Sant Pau Research Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, obtained through a simple blood test, can predict the clinical progression ...

The final stages of Alzheimer’s disease represent one of the most challenging periods for families watching their loved ones navigate this devastating condition. Understanding the critical signs that ...

TSPO levels rise early in Alzheimer’s and persist throughout disease. Targeting this biomarker could open new treatment options. TSPO, a major marker of brain inflammation, may offer a way to detect ...

A new "highly accurate" blood test for Alzheimer’s disease also measures how far it has progressed. It could help enable personalized treatment for dementia patients, say scientists. Several blood ...

While our understanding of Alzheimer’s disease is far from complete, the latest therapies, and others in more than 100 ...

Microglia are known to play an important role in Alzheimer's disease, but exactly what they do has remained a mystery. Scientists in the Bart De Strooper Lab at the VIB-KU Leuven Center for Brain & ...

New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...

Alzheimer’s disease medicines typically help reduce and manage symptoms. They do not treat the cause of Alzheimer’s disease. Kisunla offers a new approach to treat early Alzheimer’s disease. It ...